Tag: Cereno Scientific

Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy Without Bleeding Risk Supports Broad Potential in Cardiopulmonary Diseases

Coronary/Structural Heart by 0 comments

GOTHENBURG, Sweden, Jan. 14, 2026 /PRNewswire/ — Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced the publication of the first peer-reviewed…

Continue Reading →

Cereno Scientific Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)

Coronary/Structural Heart by 0 comments

GOTHENBURG, Sweden, Dec. 8, 2025 /PRNewswire/ — Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration…

Continue Reading →

Cereno Scientific Expands Footprint Into the United States With a Subsidiary in Boston, MA

Financial by 0 comments

STOCKHOLM, May 13, 2020 /PRNewswire/ — Cereno Scientific today announced that the company has expanded its global footprint by establishing a subsidiary with new office space located in Kendall Square at the Cambridge Innovation Center (CIC), Cambridge, Boston, Massachusetts. The CIC is one of the industry’s most recognized biotechnology hubs and has supported more than […]

Continue Reading →